Recombinant Full Length Meyerozyma Guilliermondii Altered Inheritance Of Mitochondria Protein 11(Aim11) Protein, His-Tagged

• Cat.No.: RFL5766MF
• Product Overview: Recombinant Full Length Meyerozyma guilliermondii Altered inheritance of mitochondria protein 11(AIM11) Protein (A5DJS9) (1-155aa), fused to N-terminal His tag, was expressed in E. coli.

Specification

• Source: E.coli expression system
• Species: Meyerozyma guilliermondii (strain ATCC 6260 / CBS 566 / DSM 6381 / JCM 1539 / NBRC 10279 / NRRL Y-324) (Yeast) (Candida guilliermondii)
• Tag: His
• Form: Lyophilized powder
• Protein Length: Full Length (1-155)
• AA Sequence: MSFTNLLEKYDFKLASASEEYKQRR KYQMALFMASGAATIFAARFAFKST MARQYVPTLF QGNHQPPTSYNFTTDAAVAVGTGTV LCGSVSSMIIFGTCWMMDVSTFKEF GWRMKTVMGG YEKQKQLAQMPLDEESEIIQNGLND ILEGKYDDIE
• Purity: Greater than 90% as determined by SDS-PAGE.
• Notes: Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
• Storage: Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
• Storage Buffer: Tris/PBS-based buffer, 6% Trehalose, pH 8.0
• Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
• Gene Name: AIM11
• Synonyms: AIM11; PGUG_03530; Altered inheritance of mitochondria protein 11
• UniProt ID: A5DJS9

Gene Information

• Gene Name: AIM11
• Synonyms: AIM11; PGUG_03530; Altered inheritance of mitochondria protein 11
• UniProt ID: A5DJS9

Reviews

12/03/2020

Its exceptional purity, stability, and reliability guarantee precise and consistent results, elevating the outcome of my research endeavors to new heights.

08/04/2017

the manufacturer of the AIM11 protein offers unparalleled technical support, ensuring any challenges or concerns that may arise are promptly addressed and resolved.

11/15/2015

The AIM11 protein surpasses the highest standards of quality, making it the ideal choice to fulfill my experimental requirements.

06/02/2015

By utilizing the AIM11 protein in combination with the manufacturer's remarkable technical support, I am certain that I can overcome any obstacles encountered along my scientific journey.

Q&As

What are some diseases or conditions that may be associated with AIM11 protein?

Research suggests that AIM11 protein may play a role in certain autoimmune diseases, such as rheumatoid arthritis and lupus, as well as inflammatory bowel disease and various types of cancer. Dysregulation of AIM11 expression and signaling has been linked to the development of these disorders.

How is AIM11 protein related to inflammation?

AIM11 protein is thought to play a role in regulating inflammation in the body. Specifically, AIM11 has been shown to interact with various components of the immune system that are involved in the inflammatory response, including macrophages and cytokines. AIM11 may act to dampen or limit the inflammatory response in certain circumstances, such as when it is necessary to prevent tissue damage or autoimmunity. However, in other circumstances, dysregulated AIM11 signaling may contribute to chronic inflammation and disease progression.

How is AIM11 protein related to cancer?

AIM11 protein has been shown to play a role in the development and progression of various types of cancer, including breast cancer, lung cancer, and colorectal cancer. AIM11 can promote cancer cell growth and survival by regulating cell signaling pathways that contribute to tumor progression. Additionally, AIM11 may suppress the immune system's ability to recognize and eliminate cancer cells, allowing the tumors to grow and spread. Targeting AIM11 may therefore be a potential strategy for cancer treatment.

What type of cells produce AIM11 protein?

AIM11 protein is produced by immune cells such as macrophages and T cells.

Can AIM11 protein be used as a diagnostic or prognostic marker for diseases?

There is some evidence to suggest that AIM11 protein levels may be useful as a diagnostic or prognostic marker for certain diseases. For example, in some studies, elevated levels of AIM11 in blood or tissue samples have been associated with increased risk or severity of autoimmune diseases like rheumatoid arthritis or lupus. Similarly, lower levels of AIM11 have been associated with increased risk of developing certain types of cancer. However, more research is needed to validate the use of AIM11 as a diagnostic or prognostic marker in clinical settings.

Can lifestyle factors or dietary interventions affect AIM11 protein expression or activity?

There is some evidence to suggest that lifestyle factors, such as diet and exercise, may affect AIM11 protein expression or activity. For example, in some studies, dietary interventions like calorie restriction or high-fat diets have been shown to influence AIM11 levels in animal models. Similarly, exercise has been shown to upregulate AIM11 mRNA expression in skeletal muscle. However, the mechanisms by which these interventions interact with AIM11 are not fully understood, and more research is needed to determine the extent to which lifestyle factors can modulate AIM11 activity in humans.

Are there any known side effects or risks associated with targeting AIM11 protein for therapy?

As with any therapeutic strategy, there is always a potential for side effects or adverse reactions when targeting AIM11. However, to date, there have not been many studies examining the safety profile of AIM11-targeted therapies specifically. Some potential risks or side effects that may be associated with AIM11-targeted therapies could include autoimmune reactions, activation of off-target immune responses, or dysregulated inflammation. It is important for researchers and clinicians to carefully evaluate the safety and efficacy of any AIM11-targeted therapy before implementing it in a clinical setting.

Is there a genetic basis for dysregulation of AIM11 protein expression?

There is some evidence to suggest that genetic variations may contribute to dysregulation of AIM11 expression and signaling. For example, certain single nucleotide polymorphisms (SNPs) in the AIM11 gene have been associated with increased risk of developing autoimmune diseases and cancer. However, more research is needed to fully understand the genetic basis of AIM11 dysregulation and its implications for disease.

Can AIM11 protein be used as a diagnostic tool?

There is ongoing research looking at the potential use of AIM11 protein as a diagnostic tool for certain diseases. However, more studies need to be done to determine the accuracy and reliability of AIM11 as a diagnostic marker.

What techniques are used to study AIM11 protein?

Researchers use a variety of techniques to study AIM11 protein, including molecular biology, biochemistry, immunology, and cell biology approaches. Some common techniques used to study AIM11 and its function include Western blotting, immunohistochemistry, flow cytometry, ELISA, and microscopy. Additionally, researchers may use animal models or cell culture systems to study the effects of AIM11 dysregulation or targeted therapeutics.

Is AIM11 protein well-understood by scientists?

AIM11 protein is a relatively new discovery and is still being studied by scientists. However, there is already a significant amount of research being done to better understand the protein and how it functions in the body.

Are there any known side effects of targeting AIM11 protein for therapeutic purposes?

It is still early in the development of AIM11-targeted therapies, so the side effects of such treatments are not yet fully understood. However, as with any therapeutic approach, the potential benefits and risks need to be carefully evaluated and balanced.

Are there any ongoing clinical trials targeting AIM11 for therapeutic purposes?

There are currently several clinical trials underway that are investigating the use of AIM11-targeted therapies for various disease indications. These trials primarily include phase I and II studies evaluating the safety and efficacy of AIM11 inhibitors or enhancers in patients with autoimmune diseases or cancer. Some of these studies are also exploring the use of AIM11 as a biomarker to predict patient response to treatment.

How can studying AIM11 protein lead to the development of new treatments?

Understanding the function and regulation of AIM11 protein can provide insights into the mechanisms underlying autoimmune diseases, inflammatory disorders, and cancers. This knowledge can help researchers develop new therapies that target AIM11 protein or its downstream pathways, which could potentially lead to more effective treatments for these conditions.

What are some potential therapeutic strategies for targeting AIM11 protein?

There are a few potential approaches for targeting AIM11 protein for therapeutic purposes. One strategy is to develop drugs or biologics that can block or inhibit the activity of AIM11. Another approach is to enhance the levels or activity of AIM11, which may be beneficial in certain conditions where AIM11 is low or dysregulated. Additionally, researchers are exploring the idea of using AIM11 as a biomarker to predict disease progression or response to treatment.

How is AIM11 protein regulated in the body?

The expression and activity of AIM11 protein is regulated by a complex interplay of various factors, including cytokines, hormones, and other signaling molecules. The regulation of AIM11 is important for maintaining the balance of the immune system and preventing excessive inflammation.

How does AIM11 protein regulate cytokine production?

AIM11 protein regulates cytokine production by activating specific signaling pathways in immune cells. This activation leads to the production of cytokines, which are important for the induction and maintenance of immune responses.